Condition: Metastatic Colorectal Cancer · Sponsor: Shanghai Henlius Biotech
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)
This description comes directly from the study's public registry record.
Ruihua Xu · 020-87343292 · xurh@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Center for Cancer Prevention and Treatment of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Linyi Cancer Hospital | Linyi, China | Recruiting |
| Fudan University Affiliated Oncology Hospital | Shanghai, China | Recruiting |
| National Cancer Center | Kashiwa, Japan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04547166